1. A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA. (June 2017) Authors: Morschhauser, F.; Le Gouill, S.; Feugier, P.; Van Den Neste, E.; Nicolas‐Virelizier, E.; Bijou, F.; Salles, G.A.; Tilly, H.; Van Eygen, K.; Van Hoof, A.; Bonnet, C.; Haioun, C.; Bouabdallah, R.; Fabiani, B.; Xerri, L.; Cartron, G.; Houot, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). (12th June 2019) Authors: Gallamini, A.; Schiano de Colella, J.; Viotti, J.; Bijou, F.; Rambaldi, A.; Perrot, A.; Patti, C.; Gastaud, L.; Sorasio, R.; Debaigt, C.; Schiappa, R.; Chamorey, E.; Viviani, S.; Thyss, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). (June 2017) Authors: Gallamini, A.; Bijou, F.; Viotti, J.; Rossi, A.; Perrot, A.; Patti, C.; Gastaud, L.; Sorasio, R.; Debaigt, C.; Chamorey, E.; Viviani, S.; Thyss, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. (12th June 2019) Authors: Jacobsen, E.; Ďuraš, J.; Ardeshna, K.; Cherry, M.; Offner, F.; Mayer, J.; Bijou, F.; Tani, M.; Musuraca, G.; Merli, M.; Marasca, R.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Zinzani, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. IBRUTINIB ABOVE 79 YEARS OLD FOR CHRONIC LYMPHOCYTIC LEUKEMIA: IMPORTANT TOXICITIES. (12th June 2019) Authors: Calleja, A.; Branco, B.; Teste, A.; Bijou, F.; Clavert, A.; Brion, A.; Laribi, K.; Oberic, L.; Guieze, R.; Michallet, A.; Ysebaert, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK. (June 2017) Authors: Soussain, C.; Choquet, S.; Houillier, C.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas‐Virelizier, E.; Barrie, M.; Moluçon‐Chabrot, C.; Lelez, M.; Clavert, A.; Coisy, S.; de la Bretonnière, M. Ertault; El Yamani, A.; Touitou, V.; Cassoux, N.; Boussetta, S.; Broussais, F.; Gelas‐Dore, B. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. (August 2019) Authors: Soussain, C.; Choquet, S.; Blonski, M.; Leclercq, D.; Houillier, C.; Rezai, K.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas-Virelizier, E.; Barrie, M.; Moluçon-Chabrot, C.; Lelez, M.L.; Clavert, A.; Coisy, S.; Leruez, S.; Touitou, V.; Cassoux, N.; Daniau, M. Journal: European journal of cancer Issue: Volume 117(2019) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OUTCOME OF PATIENTS WITH C‐MYC REARRANGED DIFFUSE LARGE B CELL LYMPHOMA ASSOCIATED OR NOT WITH BCL2 AND/OR BCL6 REARRANGEMENT: A MULTICENTRIC AND RETROSPECTIVE STUDY. (12th June 2019) Authors: Favre, S.; Botella‐Garcia, C.; Bijou, F.; Deau‐Fisher, B.; Banos, A.; Rispal, P.; Saint‐Lézer, A.; Fitoussi, O.; Lifermann, F.; Labouré, G.; Dagada, C.; Milpied, N.; Bouabdallah, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. (23rd June 2022) Authors: Cartron, G.; Bachy, E.; Tilly, H.; Daguindau, N.; Pica, G.-M.; Bijou, F.; Mounier, C.; Clavert, A. M.; Damaj, G. L.; Slama, B.; Casasnovas, O.; Houot, R.; Bouabdallah, K.; Sibon, D.; Fitoussi, O.; Morineau, N.; Herbaux, C.; Gastinne, T.; Fornecker, L.-M.; Haioun, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY. (23rd June 2022) Authors: Opat, S.; Hu, B.; Tedeschi, A.; Linton, K. M.; McKay, P.; Chan, H.; Jin, J.; Sun, M.; Sobieraj-Teague, M.; Zinzani, P. L.; Coleman, M.; Browett, P.; Ke, X.; Portell, C. A.; Thieblemont, C.; Ardeshna, K.; Bijou, F.; Walker, P.; Hawkes, E. A.; Ho, S.-J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗